| Cash Flow | 2025-07-31 |
|---|---|
| Net loss | -2,054,994 |
| Depreciation | 7,111 |
| Amortization of debt discounts and deferred financing costs | 109,950 |
| Amortization - right-of-use assets, operating lease | 24,564 |
| Stock-based compensation | 174,558 |
| Accounts receivable | -4,350 |
| Inventory | -760 |
| Prepaid and other current assets | 97,746 |
| Deferred offering costs | 224,900 |
| Accounts payable | -35,436 |
| Accrued liabilities | 166,718 |
| Lease liability, operating lease | -28,302 |
| Net cash used in operating activities | -1,953,367 |
| Acquisition of intellectual property - intangibles | 814 |
| Net cash used in investing activities | -814 |
| Issuance of series d preferred stock and warrants, net of issuance costs | 3,796,376 |
| Principal repayments on the streeterville note | 100,000 |
| Repayments of financed insurance premiums | 48,062 |
| Net cash provided by financing activities | 3,648,314 |
| Net change in cash and cash equivalents during the period | 1,694,133 |
HeartSciences Inc. (HSCSW)
HeartSciences Inc. (HSCSW)